Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials.
Wiley Interdiscip Rev Nanomed Nanobiotechnol
; 15(3): e1867, 2023.
Article
en En
| MEDLINE
| ID: mdl-36308008
ABSTRACT
Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials. This article is categorized under Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Nanopartículas
/
Neoplasias
Tipo de estudio:
Clinical_trials
Límite:
Humans
/
Male
Idioma:
En
Revista:
Wiley Interdiscip Rev Nanomed Nanobiotechnol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos